title: Effect of paclitaxel-loaded nanoparticles on the viability of human hepatocellular carcinoma HepG2 cells.
abstract: OBJECTIVE
  To explore effects of paclitaxel-loaded poly lactic-co-glycolic acid (PLGA) particles on the viability of human hepatocellular carcinoma (HCC) HepG2 cells.
  
  
  METHODS
  The viability of HepG2 cells was assessed using MTT under different concentrations of prepared paclitaxel-loaded particles and paclitaxel (6.25, 12.5, 25, 50, and 100 mg/L), and apoptosis was analyzed using Hochest33342/Annexin V-FITC/PI combined with an IN Cell Analyzer 2000.
  
  
  RESULTS
  Paxlitaxel-loaded nanoparticles were characterized by narrow particle size distribution (158.6 nm average particle size). The survival rate of HepG2 cells exposed to paclitaxel-loaded PLGA particles decreased with the increase of concentration and time period (P<0.01 or P<0.05), the dose- and time-dependence indicating sustained release (P<0.05). Moreover, apoptosis of HepG2 cells was induced, again with an obvious dose- and time-effect relationship (P<0.05).
  
  
  CONCLUSIONS
  Paclitaxel-loaded PLGA particles can inhibit the proliferation and induce the apoptosis of HCC HepG2 cells. This new-type of paclitaxel carrier body is easily made and has low cost, good nanoparticle characterization and sustained release. Hence, paclitaxel- loaded PLGA particles deserve to be widely popularized in the clinic.
authors.affiliation: Pharmacy Department, The 208th Hospital of PLA., Changchun, China E-mail : zqi8229@126.com.
authors.forename: Zhi-Hong
authors.initials: ZH
authors.lastname: Hou
authors.forename: Wen-Cui
authors.initials: WC
authors.lastname: Zhao
authors.forename: Qi
authors.initials: Q
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: Zheng
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004337:Drug Carriers / Q000627:therapeutic use*; D056945:Hep G2 Cells; D006801:Humans; D019344:Lactic Acid / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000188:drug therapy*; D053758:Nanoparticles / Q000627:therapeutic use*; D017239:Paclitaxel / Q000627:therapeutic use*; D011100:Polyglycolic Acid / Q000627:therapeutic use; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D017239:Paclitaxel